StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)

Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –

Exelixis total assets

Total assets on the balance sheet at the end of each period.

Exelixis's total assets was $2.51B at Oct 2, 2026. For fiscal 2025 it was $2.84B, down 3.5% from the year before. Over ten years it grew 23.9% a year on average. The highest annual figure on record is $3.07B in fiscal 2022.

Annual total assets

PeriodPeriod endValueChange
FY2025Jan 2, 2026$2.84B-3.5%
FY2024Jan 3, 2025$2.95B+0.2%
FY2023Dec 29, 2023$2.94B-4.2%
FY2022Dec 30, 2022$3.07B+17.4%
FY2021Dec 31, 2021$2.62B+22.4%
FY2020Jan 1, 2021$2.14B+13.3%
FY2019Jan 3, 2020$1.89B+32.6%
FY2018Dec 28, 2018$1.42B+117.0%
FY2017Dec 29, 2017$655.29M+10.0%
FY2016Dec 31, 2016$595.74M+79.3%
FY2015Dec 31, 2015$332.34M+2.8%
FY2014Dec 31, 2014$323.27M-35.8%
FY2013Dec 31, 2013$503.29M-30.2%
FY2012Dec 31, 2012$721.10M+83.4%
FY2011Dec 31, 2011$393.26M+9.0%
FY2010Dec 31, 2010$360.79M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Oct 2, 2026$2.51B-11.0%
Q2 FY2026Jul 3, 2026$2.49B-6.9%
Q1 FY2026Apr 3, 2026$2.59B-8.6%
Q4 FY2025Jan 2, 2026$2.84B-3.5%
Q3 FY2025Oct 3, 2025$2.82B-4.6%
Q2 FY2025Jul 4, 2025$2.68B-3.4%
Q1 FY2025Apr 4, 2025$2.84B+1.2%
Q4 FY2024Jan 3, 2025$2.95B+0.2%
Q3 FY2024Sep 27, 2024$2.96B-0.6%
Q2 FY2024Jun 28, 2024$2.77B-11.8%
Q1 FY2024Mar 29, 2024$2.80B-10.8%
Q4 FY2023Dec 29, 2023$2.94B-4.2%
Q3 FY2023Sep 29, 2023$2.98B+0.5%
Q2 FY2023Jun 30, 2023$3.14B+9.1%
Q1 FY2023Mar 31, 2023$3.14B+18.4%
Q4 FY2022Dec 30, 2022$3.07B+17.4%
Q3 FY2022Sep 30, 2022$2.96B+21.0%
Q2 FY2022Jul 1, 2022$2.88B+21.7%
Q1 FY2022Apr 1, 2022$2.65B+21.2%
Q4 FY2021Dec 31, 2021$2.62B+22.4%
Q3 FY2021Oct 1, 2021$2.45B+15.9%
Q2 FY2021Jul 2, 2021$2.37B+15.7%
Q1 FY2021Apr 2, 2021$2.19B+12.0%
Q4 FY2020Jan 1, 2021$2.14B+13.3%
Q3 FY2020Oct 2, 2020$2.11B+18.3%
Q2 FY2020Jul 3, 2020$2.05B+24.6%
Q1 FY2020Apr 3, 2020$1.96B+26.8%
Q4 FY2019Jan 3, 2020$1.89B+32.6%
Q3 FY2019Sep 27, 2019$1.78B+74.2%
Q2 FY2019Jun 28, 2019$1.64B+80.3%
Q1 FY2019Mar 29, 2019$1.54B+99.0%
Q4 FY2018Dec 28, 2018$1.42B+117.0%
Q3 FY2018Sep 28, 2018$1.02B+68.0%
Q2 FY2018Jun 29, 2018$911.16M+76.4%
Q1 FY2018Mar 30, 2018$774.92M+32.0%
Q4 FY2017Dec 29, 2017$655.29M+10.0%
Q3 FY2017Sep 30, 2017$609.77M–
Q2 FY2017Jun 30, 2017$516.53M–
Q1 FY2017Mar 31, 2017$586.98M–
Q4 FY2016Dec 31, 2016$595.74M–

More Exelixis figures

See a number that looks wrong?